Harvard
Cohen, O, Ronen, O, Khafif, A, Rodrigo, JP, Simo, R, Pace-Asciak, P, Randolph, G
, Mikkelsen, LH, Kowalski, LP, Olsen, KD, Sanabria, A, Tufano, RP, Babighian, S, Shaha, AR, Zafereo, M & Ferlito, A 2022, '
Revisiting the role of surgery in the treatment of Graves' disease',
Clinical Endocrinology, bind 96, nr. 6, s. 747-757.
https://doi.org/10.1111/cen.14653APA
Cohen, O., Ronen, O., Khafif, A., Rodrigo, J. P., Simo, R., Pace-Asciak, P., Randolph, G.
, Mikkelsen, L. H., Kowalski, L. P., Olsen, K. D., Sanabria, A., Tufano, R. P., Babighian, S., Shaha, A. R., Zafereo, M., & Ferlito, A. (2022).
Revisiting the role of surgery in the treatment of Graves' disease.
Clinical Endocrinology,
96(6), 747-757.
https://doi.org/10.1111/cen.14653CBE
Cohen O, Ronen O, Khafif A, Rodrigo JP, Simo R, Pace-Asciak P, Randolph G
, Mikkelsen LH, Kowalski LP, Olsen KD, Sanabria A, Tufano RP, Babighian S, Shaha AR, Zafereo M, Ferlito A. 2022.
Revisiting the role of surgery in the treatment of Graves' disease.
Clinical Endocrinology. 96(6):747-757.
https://doi.org/10.1111/cen.14653MLA
Vancouver
Author
Cohen, Oded ; Ronen, Ohad ; Khafif, Avi ; Rodrigo, Juan P ; Simo, Ricard ; Pace-Asciak, Pia ; Randolph, Gregory
; Mikkelsen, Lauge H ; Kowalski, Luiz P ; Olsen, Kerry D ; Sanabria, Alvaro ; Tufano, Ralph P ; Babighian, Silvia ; Shaha, Ashok R ; Zafereo, Mark ; Ferlito, Alfio. /
Revisiting the role of surgery in the treatment of Graves' disease. I:
Clinical Endocrinology. 2022 ; Bind 96, Nr. 6. s. 747-757.
Bibtex
@article{443f911bf47942ceac48dd78b087c027,
title = "Revisiting the role of surgery in the treatment of Graves' disease",
abstract = "Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.",
keywords = "Antithyroid Agents/therapeutic use, Graves Disease/drug therapy, Humans, Iodine Radioisotopes/therapeutic use, Thyroid Neoplasms/surgery, Thyroidectomy",
author = "Oded Cohen and Ohad Ronen and Avi Khafif and Rodrigo, {Juan P} and Ricard Simo and Pia Pace-Asciak and Gregory Randolph and Mikkelsen, {Lauge H} and Kowalski, {Luiz P} and Olsen, {Kerry D} and Alvaro Sanabria and Tufano, {Ralph P} and Silvia Babighian and Shaha, {Ashok R} and Mark Zafereo and Alfio Ferlito",
note = "{\textcopyright} 2021 John Wiley & Sons Ltd.",
year = "2022",
month = jun,
doi = "10.1111/cen.14653",
language = "English",
volume = "96",
pages = "747--757",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",
}
RIS
TY - JOUR
T1 - Revisiting the role of surgery in the treatment of Graves' disease
AU - Cohen, Oded
AU - Ronen, Ohad
AU - Khafif, Avi
AU - Rodrigo, Juan P
AU - Simo, Ricard
AU - Pace-Asciak, Pia
AU - Randolph, Gregory
AU - Mikkelsen, Lauge H
AU - Kowalski, Luiz P
AU - Olsen, Kerry D
AU - Sanabria, Alvaro
AU - Tufano, Ralph P
AU - Babighian, Silvia
AU - Shaha, Ashok R
AU - Zafereo, Mark
AU - Ferlito, Alfio
N1 - © 2021 John Wiley & Sons Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.
AB - Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.
KW - Antithyroid Agents/therapeutic use
KW - Graves Disease/drug therapy
KW - Humans
KW - Iodine Radioisotopes/therapeutic use
KW - Thyroid Neoplasms/surgery
KW - Thyroidectomy
UR - http://www.scopus.com/inward/record.url?scp=85121735496&partnerID=8YFLogxK
U2 - 10.1111/cen.14653
DO - 10.1111/cen.14653
M3 - Review
C2 - 34954838
VL - 96
SP - 747
EP - 757
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 6
ER -
